Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Imfinzi Trial Does Not Meet Primary Endpoint

americanpharmaceuticalreviewFebruary 10, 2021

Tag: Imfinzi , extreme , AstraZeneca , PD-L1 , KESTREL

PharmaSources Customer Service